Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains ...

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August, the U.S. drugmaker said on Monday.

Regeneron acquired a promising weight management asset that could become lucrative. Shares of Regeneron (NASDAQ: REGN) have declined this year due to issues with one of its former growth drivers, ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both have witnessed rapid demand despite being on the market for less than ...